Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

NCT00030381 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

22

Enrollment

NIH

Sponsor class

Stopped Administratively complete.

Conditions

Primary Systemic Amyloidosis

Interventions

DRUG: 4'-iodo-4'-deoxydoxorubicin
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)